Johnson & Johnson (JNJ) News
Filter JNJ News Items
JNJ News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
JNJ News Highlights
- JNJ's 30 day story count now stands at 29.
- Over the past 24 days, the trend for JNJ's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
- DOW, DRUG and META are the most mentioned tickers in articles about JNJ.
Latest JNJ News From Around the Web
Below are the latest news stories about JOHNSON & JOHNSON that investors may wish to consider to help them evaluate JNJ as an investment opportunity.
Dividend Stock Portfolio: 15 Stocks To Buy According to RedditIn this article, we discuss 15 dividend stocks to buy according to Reddit. You can skip our detailed analysis of dividend stocks and the role of retail investors in today’s stock market, and go directly to read Dividend Stock Portfolio: 5 Stocks To Buy According to Reddit. While tech stocks outperformed dividend stocks in the […] |
3 Best Stocks to Buy in September and Hold ForeverThere will always be a healthcare industry, and it will always be a place to find great long-term stocks. You probably know healthcare conglomerate Johnson & Johnson for some of its former brands, like Tylenol and Band-Aids. |
20 Most Innovative Companies in AmericaIn this article, we will take a look at the most innovative companies in America. If you want to explore similar companies, you can go to 5 Most Innovative Companies in America. Innovation and American Companies Innovation comes with new and creative ideas that bring a healthy change in society. Innovation in business and technology […] |
Here is What to Know Beyond Why Johnson & Johnson (JNJ) is a Trending StockZacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects. |
Blockbuster Cancer Treatment Stymied by Supply Chain—for NowA cell therapy for multiple myeloma promises to be a major blockbuster for J&J and partner Legend, if they can increase manufacturing. |
Rockville life sciences firm Emmes names former J&J exec Peter Ronco as its new CEORockville clinical research organization The Emmes Co. has tapped a former Johnson & Johnson and Bristol Myers-Squibb Co. executive to be its next CEO. The company, which conducts research for public- and private-sector clients, announced Wednesday that Peter Ronco will replace replace Dr. Christine Dingivan as CEO, effective immediately. Dingivan, Emmes’ CEO since September 2020, will serve as a senior adviser to Executive Chairman Sastry Chilukiri and Emmes’ board of directors, the company said in an announcement. |
Consumers seek consolidation of class actions against P&G, Johnson & Johnson over decongestantPlaintiffs suing Procter & Gamble and other drug companies over a supposedly ineffective nasal decongestant are asking a federal panel to consolidate the cases in New Jersey District Court. |
Buying These 2 Stocks Is a Good Way to Hedge Against a Market CrashNo one likes to think about a market crash, but the best way to stay afloat through such a time is to think ahead, plan, and be prepared. You could hedge against a market crash by choosing stocks that probably won't plummet during the worst of times and are sure to thrive over time. Market leaders and companies with either strong brand strength or products people can't avoid buying are good candidates. |
3 No-Brainer Stocks to Buy With $500 Right NowSince the beginning of the decade, Wall Street's major stock indexes have navigated their way through two bear markets. Although they've rebounded in a big way from their 2022 bear market lows, the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite remain firmly below their all-time highs. What this represents is an opportunity for patient investors to pounce on plain-as-day bargains. |
7 Safe and Steady Dividend Stocks to Buy for Volatile TimeAmid a turbulent market landscape, these companies offer safe dividend stocks, combining robust financials with promising future prospects. |